Equities

Henan Lingrui Pharmaceutical Co Ltd

600285:SHH

Henan Lingrui Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)19.07
  • Today's Change-0.11 / -0.57%
  • Shares traded9.39m
  • 1 Year change+9.22%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,5861,4551,222
Total Receivables, Net518533441
Total Inventory467486428
Prepaid expenses183440
Other current assets, total8.620.01--
Total current assets2,5992,5082,131
Property, plant & equipment, net678745787
Goodwill, net00--
Intangibles, net230242286
Long term investments1,069677456
Note receivable - long term------
Other long term assets------
Total assets4,7724,3443,793
LIABILITIES
Accounts payable576878
Accrued expenses1,124938611
Notes payable/short-term debt233182296
Current portion long-term debt/capital leases1.081.221.65
Other current liabilities, total484523452
Total current liabilities1,9001,7121,438
Total long term debt6.966.207.90
Total debt241189305
Deferred income tax262918
Minority interest7.667.557.59
Other liabilities, total403943
Total liabilities1,9811,7931,514
SHAREHOLDERS EQUITY
Common stock567567568
Additional paid-in capital326310272
Retained earnings (accumulated deficit)1,8941,6651,481
Treasury stock - common(47)(68)(98)
Unrealized gain (loss)46----
Other equity, total4.847756
Total equity2,7912,5512,279
Total liabilities & shareholders' equity4,7724,3443,793
Total common shares outstanding563559554
Treasury shares - common primary issue3.968.1314
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.